ResMed Balance Sheet Health
Financial Health criteria checks 6/6
ResMed has a total shareholder equity of $5.2B and total debt of $677.5M, which brings its debt-to-equity ratio to 13%. Its total assets and total liabilities are $7.2B and $2.0B respectively. ResMed's EBIT is $1.5B making its interest coverage ratio 41. It has cash and short-term investments of $442.6M.
Key information
13.0%
Debt to equity ratio
US$677.47m
Debt
| Interest coverage ratio | 41x |
| Cash | US$442.58m |
| Equity | US$5.20b |
| Total liabilities | US$2.03b |
| Total assets | US$7.22b |
Recent financial health updates
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26Recent updates
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Nov 13We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Oct 20ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price
Oct 08Why ResMed's Rally Is Just Getting Started
Sep 18ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors
Sep 13ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26Financial Position Analysis
Short Term Liabilities: RMD's short term assets ($2.6B) exceed its short term liabilities ($904.1M).
Long Term Liabilities: RMD's short term assets ($2.6B) exceed its long term liabilities ($1.1B).
Debt to Equity History and Analysis
Debt Level: RMD's net debt to equity ratio (4.5%) is considered satisfactory.
Reducing Debt: RMD's debt to equity ratio has reduced from 57.6% to 13% over the past 5 years.
Debt Coverage: RMD's debt is well covered by operating cash flow (212.6%).
Interest Coverage: RMD's interest payments on its debt are well covered by EBIT (41x coverage).